A type III polyketide synthase mutant for the production of alkyl resorcinol and its application

By mutating the amino acid sequence of type III polyketide synthase, high-activity enzyme mutants T272A/L271V or T272A/Y342V were obtained, solving the problem of low catalytic efficiency and significantly improving the production capacity of alkyl resorcinol.

CN123107952APending Publication Date: 2026-11-17BY HEALTH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611463120.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing type III polyketide synthase has low catalytic efficiency, which limits the production of alkylresorcinol.

Method used

By performing various mutations and screenings on type III polyketide synthase, high-activity enzyme mutants were obtained, especially the mutants T272A/L271V or T272A/Y342V, which enhanced the ability to catalyze the production of alkyl resorcinol.

Benefits of technology

The ability to catalyze the production of alkylresorcinol was nearly doubled, laying the foundation for further metabolic engineering of E. coli to produce alkylresorcinol.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107952A_ABST
    Figure CN123107952A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of bioenzyme engineering technology, specifically, it relates to a type III polyketide synthase mutant for the production of alkylresorcinol and its applications. Through screening and enzyme mutation, this invention obtained a type III polyketide synthase mutant capable of efficiently producing alkylresorcinol. In particular, after mutations in T272A / L271V or T272A / Y342V, the ability of this type III polyketide synthase mutant to catalyze the production of alkylresorcinol was nearly doubled. The technical solution of this invention lays the foundation for further metabolic engineering of *E. coli* to produce alkylresorcinol and has promising prospects for industrial application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bioenzyme engineering technology. In particular, this invention relates to a type III polyketide synthase mutant for the production of alkyl resorcinol and its application. Background Technology

[0002] Alkylresorcinols (ARs) are a class of derivatives of 1,3-resorcinol, in which the 5-position of the benzene ring is replaced by an alkyl group containing an odd number of carbon atoms. They belong to the phenolic lipid family. ARs were first discovered in 1995 in cereals such as wheat, and are amphiphilic phenolic compounds. Since then, they have also been found in many other plants, including sorghum, rice, corn, ginkgo, and mango. In recent years, research has found that phenolic compounds in whole grains and other plant-based foods have various health benefits, such as preventing colorectal cancer, cardiovascular disease, obesity, and diabetes. Alkylresorcinols (ARs) constitute a large proportion of cereal phenols and are important active ingredients and markers of the cereal bran. Currently, the main industrial production methods for ARs include plant extraction. Plant extraction requires whole grains as raw materials and involves strong acids and alkalis, resulting in environmental pollution, limited raw material sources, and potential allergenicity. With the development of genetic engineering technology, biosynthesis is gaining increasing attention due to its scalability and lower cost. Type III polyketide synthases are a class of multifunctional enzymes responsible for catalyzing the synthesis of diverse and highly bioactive natural products. They utilize fatty acyl-CoA of varying chain lengths (such as acyl-CoA) as starting units and iteratively condense with malonyl-CoA (as an extension unit) to construct the polyketide backbone. The Type III PKS superfamily includes various functionally differentiated members such as chalcone synthase (CHS), stilbene synthase (STS), octaketone synthase (OKS), curcumin synthase (CUS), and acridinone synthase (ACS). Type III polyketide synthase is one branch within this family, capable of catalyzing the iterative condensation of fatty acyl-CoA with three malonyl-CoA molecules, followed by Claisen cyclization to generate 5-alkylresorcinol. The gradual discovery and analysis of genes within the Type III polyketide synthase family has made it possible to synthesize and produce natural products (ARs) using genetic engineering techniques.

[0003] In synthetic biology, commonly used engineered bacteria include Escherichia coli (Escherichia coli). Escherichia coliBacillus subtilis, Corynebacterium glutamicum, and others are among the strains that have been widely used due to their clear genetic background, mature and complete molecular biological manipulation element system, ease of cultivation and control, simple and efficient transformation operations, high protein expression levels, low cost, and short cycle. By introducing type III polyketide synthase encoding genes into these strains, microbial synthesis of alkyl resorcinols (ARs) can be achieved. However, the catalytic efficiency of existing type III polyketide synthases is relatively low, limiting the production of alkyl resorcinols. Targeted enzyme modification and fermentation screening to obtain superior enzyme mutants not only helps in-depth research into the catalytic mechanism of type III polyketide synthases but also has significant implications for further modifying enzyme molecules, improving the ability of E. coli to produce alkyl resorcinols, and expanding fermentation production applications. Summary of the Invention

[0004] To address the problems of insufficient enzyme activity and low catalytic efficiency of existing type III polyketide synthase used for the production of alkyl resorcinol, the inventors conducted extensive and long-term research, performing various mutations and screenings on type III polyketide synthase, and ultimately obtained a variety of high-activity enzyme mutants, thus completing this invention.

[0005] In a first aspect, the present invention discloses a type III polyketide synthase mutant for the production of alkyl resorcinol, wherein the type III polyketide synthase mutant is characterized by a mutation in amino acid residues near the substrate binding pocket of the type III polyketide synthase, and the amino acid sequence of the type III polyketide synthase is shown in SEQ ID NO.2.

[0006] In this invention, an enzyme mutant refers to a novel enzyme variant obtained by artificially altering the amino acid sequence of an enzyme. Its encoding gene or amino acid sequence differs from the wild-type enzyme and may exhibit different catalytic activities, stability, substrate specificity, and other properties. Mutant nucleotide sequences are typically obtained by point mutations, insertions, deletions, or recombinations of the enzyme's nucleotide sequence.

[0007] In some embodiments, enzyme mutants are obtained through point mutations or directed evolution.

[0008] In this invention, although the aforementioned type III polyketide synthase mutant has undergone mutations at one or several amino acid sites, it still retains the basic function of catalyzing the production of alkyl resorcinol, and its ability to catalyze synthesis is even stronger than that of the native synthase.

[0009] In some embodiments, the type III polyketide synthase mutant of the present invention is selected from any one of the following mutations 1-2 or a combination thereof: Mutation 1: Some amino acids located within the 5 Å range of the substrate binding pocket of type III polyketide synthase are mutated to alanine (Ala), which has less steric hindrance; Mutation 2: Some amino acids located within the 5 Å range of the substrate binding pocket of type III polyketide synthase are mutated to the more hydrophobic valine val.

[0010] In one aspect, the present invention discloses a type III polyketide synthase mutant for the production of alkylresorcinol, wherein the mutation of the type III polyketide synthase mutant satisfies at least one of the following conditions: (1) In mutation 1, the amino acids at positions 55, 59, 62, 63, 160, 211, 213, 217, 218, 237, 258, 271, 272, 275, 276, 314, 316, 317, 319, 320, 342, 347, and 349 of the amino acid sequence of type III polyketide synthase are mutated, and any one of these sites is mutated to alanine; (2) In mutation 2, the amino acids at positions 59, 63, 160, 211, 213, 217, 218, 258, 271, 272, 276, 316, 317, 342, 347, and 349 of the amino acid sequence of type III polyketide synthase are mutated, and any one of these sites is mutated to valine; The amino acid sequence of the type III polyketide synthase is shown in SEQ ID NO. 2.

[0011] In some embodiments, the mutation of the type III polyketide synthase mutant is any combination between mutation 1 and mutation 2.

[0012] In one aspect, the present invention discloses a type III polyketide synthase mutant, wherein the mutation of the type III polyketide synthase mutant is selected from any one of the following ①-②: ①: One or more of L211A, F218A, T272A, I213V, L271V, and Y342V; ②: One or more of L211A / I213V, F218A / I213V, F218A / L271V, F218A / Y342V, T272A / I213V, T272A / L271V, and T272A / Y342V.

[0013] In one aspect, the present invention discloses a nucleic acid molecule comprising the nucleotide sequence of the aforementioned type III polyketide synthase mutant.

[0014] In one aspect, the present invention discloses an expression vector containing the nucleotide sequence of the aforementioned type III polyketide synthase mutant.

[0015] In some embodiments, the expression vector is selected from plasmid vectors.

[0016] In one aspect, the present invention discloses a genetically engineered bacterium containing an expression vector, wherein the expression vector contains the nucleotide sequence of the aforementioned type III polyketide synthase mutant of the present invention.

[0017] In some embodiments, the chassis bacteria of the genetically engineered bacteria are one of Escherichia coli, Corynebacterium glutamicum, and Bacillus subtilis.

[0018] In one embodiment, the chassis bacteria are derived from Escherichia coli; more preferably, the Escherichia coli strain is selected from BL21, C41, OrigamB, Rosetta, Turner, JM109, HMS174, NovaBlue, AD494, Origami, and Nissle1917.

[0019] In one embodiment, the chassis bacteria are derived from Escherichia coli Nissle 1917, which does not contain pathogenic factors such as enterotoxins, hemolytic toxins, and cytotoxins, and poses no safety risk to the host.

[0020] In one embodiment, the *E. coli* Nissle 1917 is a genetically modified *E. coli* Nissle 1917, wherein the modification includes integrating a specific sequence of a T7 RNA polymerase expression cassette into a specific site of the Nissle 1917 strain, deleting a cryptic plasmid, and knocking out two additional interfering genes on the genome. endA Genes and ompT Genes; for specific modification methods, see CN202310516515.6.

[0021] In one aspect, the present invention discloses a method for producing alkylresorcinol, wherein the method uses the aforementioned type III polyketide synthase mutant of the present invention as a catalyst to catalyze the synthesis of alkylresorcinol.

[0022] Beneficial effects This invention obtained a type III polyketide synthase mutant capable of efficiently producing alkylresorcinol through screening and enzyme mutation. In particular, the ability of this type III polyketide synthase mutant to catalyze the production of alkylresorcinol was nearly doubled after mutations in T272A / L271V or T272A / Y342V. The technical solution of this invention lays the foundation for further metabolic engineering of *E. coli* to produce alkylresorcinol and has promising prospects for industrial application. Attached Figure Description

[0023] Figure 1 Schematic diagram of key sites in the substrate binding pocket mutation of type III polyketide synthase HcPKs3.

[0024] Figure 2: HPLC chromatograms of ARs, where (A) represents the HPLC results of the standard; (B) represents the HPLC results of the ARs sample.

[0025] Figure 3 Results of shake-flask fermentation yield of type III polyketide synthase HcPKs3 and its double mutant engineered strains. Detailed Implementation

[0026] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific conditions are not specified in the examples, conventional conditions, manufacturer's recommended conditions, or relevant operating instructions should be followed. The molecular biology and bioinformatics methods involved in the examples can be found in relevant textbooks, reference books, and teaching websites, including but not limited to "Bioinformatics," "Molecular Biology," "Genetic Engineering," "Molecular Cloning: A Laboratory Manual," "A Concise Laboratory Manual of Molecular Biology," and "Enzyme Engineering." Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.

[0027] Example 1: Construction of chassis strains and discovery and screening of type III polyketide synthase 1.1 Construction of Chassis Bacteria Based on Nissle1917 Probiotic E. coli EcNcΔ attB (lacUV5-T7) ΔendAΔOmpT Preparation of the substrate bacteria: Refer to CN202310516515.6 for relevant methods. The original strain was *Escherichia coli* Nissle1917 (…). E.coli Nissle 1917 In this study, based on CRISPR / Cas9 gene editing technology, the optimized T7 RNAP expression cassette was inserted into the genome of Nissle 1917 bacteria. The insertion site of the expression cassette was located on the genome. attB Sites, then knocked out endA and ompT Gene and two cryptic plasmids were used to prepare EcNcΔ attB (lacUV5-T7) ΔendAΔompT, It was named "TCBJ117".

[0028] 1.2 Discovery and Screening of Type III Polyketide Synthase Methods for discovering type III polyketide synthases based on structural analysis specifically include: based on known functionally active type III polyketide synthases... Sporotrichum laxum ATCC 15155 source Sl-PKS2 Genes as templates ( Sl-PKS2The gene (GeneBanK accession number KU560627) was used for structural similarity searching in the protein database https: / / www.uniprot.org / . Through comparison and screening, a gene with a similarity of 68.9% was selected and named... HcPKs3, Used for testing protein activity. Codons were artificially synthesized and optimized by Wuhan Tianyi Huayu Gene Technology Co., Ltd. HcPKs3 Genes were generated and expression vectors were constructed. After being transformed into the chassis strain TCBJ117, the yield of alkyl resorcinol in the engineered strain was tested. HcPKs3 The gene sequence is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2. The synthesized gene fragment was ligated into the vector pRSFDuet using a homologous recombination kit (Pro Ligation-Free Cloning Kit, abm Inc., catalog number E086) to obtain the recombinant plasmid pRSFDuet-HcPKs3. This recombinant plasmid was transformed into the chassis strain TCBJ117 to obtain the engineered strain TCBJ117-HcPKs3. The empty plasmid vector pRSFDuet was transformed into TCBJ117 as a negative control strain TCBJ117-CK. The laboratory-preserved strain TCBJ117-... Sl-PKS2 As a positive control.

[0029] Example 2: Expression and Fermentation Detection of Type III Polyketide Synthase The engineered strains TCBJ117-HcPKs3 and TCBJ117- will be obtained. Sl-PKS2 Single colonies of both strain TCBJ117-CK and the control strain were picked and inoculated into LB medium (5 g / L yeast extract, 10 g / L tryptone, 10 g / L NaCl) containing 50 μg / mL kanamycin, and cultured overnight at 37°C and 200 rpm for 12 h. The seed culture was then transferred at 1% to 100 mL of fresh LB medium (containing 50 μg / mL kanamycin), and cultured at 37°C and 200 rpm until the OD600 reached 0.6. Expression was induced by adding 0.3 mM IPTG, and fermentation was carried out at 30°C and 200 rpm for 24 h.

[0030] Collect the fermentation broth, centrifuge at 6000 rpm for 10 min, and separate the supernatant and precipitate. Add 100 mL of ethyl acetate to the supernatant, and extract by shaking at 150 rpm for 12 h, collecting the ethyl acetate layer. Add 10 mL of PBS buffer to the precipitate, sonicate for 15 min, centrifuge the cell lysate at 12000 rpm for 10 min, take the supernatant, add 100 mL of ethyl acetate, and extract by shaking at 150 rpm for 12 h, collecting the ethyl acetate layer. Mix the two batches of ethyl acetate solutions obtained from extraction, dry under vacuum by rotary evaporation, dissolve and resuspend the solid in 2 mL of methanol, filter through a 0.22 μm filter membrane, and use for liquid chromatography-mass spectrometry (LC-MS) analysis with 5-pentadecanylresorcinol (C5000).15:0 ), 5-heptadecylresorcinol (C 17:0 ), 5-Ninedecylresorcinol (C 19:0 The standard sample is used as a test marker.

[0031] The expressed products were detected by liquid chromatography and mass spectrometry: alkyl resorcinol liquid chromatography detection conditions: The products were detected using an Agilent 1200 HPLC instrument (Agilent Eclipse Plus C18, 5μm, 4.6mm×250mm), column temperature 30℃, mobile phase A: 89% (v / v) methanol aqueous solution and B: 99% (v / v) methanol aqueous solution, flow rate 0.65mL / min, elution gradient is shown in Table 1, and UV detection wavelength is 280nm.

[0032] Table 1. Elution gradient of alkylresorcinol in liquid chromatography.

[0033] MS detection conditions: Ionization method: electrospray negative ion mode; Detection method: Product Ion; Atomizing gas pressure: 40 psi; Ion spray voltage: 4000 V; Dryer temperature: 350 ℃; Drying gas flow rate: 8 L / min. Qualitative ion pairs, fragmentation voltage, and collision energy are shown in Table 2.

[0034] Table 2

[0035] Table 3. Yield of alkyl resorcinol

[0036] "-" indicates that the compound was not detected.

[0037] As shown in Table 3, the type III polyketide synthase HcPKs3 discovered was consistent with the detection product of the reference gene Sl-PKS2, and both could detect 5-pentadecanylresorcinol (C 15:0 ), 5-heptadecylresorcinol (C 17:0 ), 5-Ninedecylresorcinol (C 19:0 The yield of the engineered strain TCBJ117-HcPKs3 was higher than that of the positive control engineered strain TCBJ117-Sl-PKS2. The yield of the engineered strain TCBJ117-HcPKs3 was 24.9 mg / L, which was 10.9% higher than that of the positive control strain.

[0038] Example 3: Determination of HcPKs3 mutation site and shake-flask fermentation 3.1 Construction of HcPKs3 substrate binding pocket single mutant plasmid It is known that the synthesis of alkylresorcinol structures by type III polyketide synthases involves catalyzing a three-stage decarboxylation condensation reaction of three molecules of malonyl-CoA using a specific acyl-CoA as a substrate, followed by an aldol condensation reaction at C2 and C7 to form the product. To obtain highly efficient alkylresorcinol mutants using malonyl-CoA and fatty acyl-CoA as substrates, starting with the HcPKs3 protein obtained in Example 1, multi-scale computational bioinformatics methods, including homology modeling, molecular docking, conservation analysis, molecular dynamics simulation, and model prediction, were used to identify key amino acid residues within a 5 Å range of the substrate binding pocket. Thirty-nine mutation sites were designed (Table 4). M1-M23 primarily target the substrate binding pocket, mutating to alanine, as alanine has the least steric hindrance, resulting in the largest active pocket after mutation. M24-M39 primarily increase the hydrophobicity of the substrate binding pocket, mutating to valine.

[0039] Based on the dynamic trajectory and evolutionary conservation patterns, alanine was scanned, and potential beneficial mutation sites were screened. The following 23 key sites were selected for mutation to alanine: K55, I59, N62, T63, C160, L211, I213, I217, F218, P237, I258, L271, T272, V275, P276, H314, G316, G317, K319, V320, Y342, N347, and S349.

[0040] Based on its dynamic trajectory and evolutionary conservation patterns, valine scanning was performed to screen for potential beneficial mutation sites. The following 16 key sites were selected for mutation to valine: I59, T63, C160, L211, I213, I217, F218, I258, L271, T272, P276, G316, G317, Y342, N347, and S349. To test the activity of the HcPKs3 mutant gene, the mutant gene sequence was artificially synthesized by Wuhan Tianyi Huayu Gene Technology Co., Ltd. based on the HcPKs3 mutant amino acid sequence. The names of each mutant are shown in Table 4.

[0041] Table 4 Substrate-binding pocket single mutants

[0042] 3.2 Construction of genetically engineered strains containing mutants and determination of fermentation yield The above-mentioned single mutant gene was ligated into the vector pRSFDuet, and then electroporated into TCBJ117 to obtain a genetically engineered strain containing the mutant. Meanwhile, the engineered strain TCBJ117-HcPKs3 was used as the control strain (WT), and the fermentation process and detection methods were the same as in Example 2. Specific results are shown in Table 5.

[0043] Table 5: ARs yield of type III polyketide synthase mutants

[0044] This embodiment yielded six positive mutants with significantly increased ARs yield. Among the 23 mutants M1-M23 mutated to alanine, three positive mutants with significantly increased ARs yield were obtained: M6, M9, and M13. Specifically, the mutations were: leucine at position 211 mutated to alanine (L211A), phenylalanine at position 218 mutated to alanine (F218A), and threonine at position 272 mutated to alanine (T272A). After 24 h of fermentation, the yield of M6 (L211A) reached 42.5 mg / L, an increase of 70.68% compared to the control strain; the yield of M9 (F218A) reached 27.4 mg / L, an increase of 10.04% compared to the control strain; and the yield of M13 (T272A) reached 51.3 mg / L, an increase of 106.02% compared to the control strain.

[0045] Among the 16 mutants with M24-M39 mutated to valine, three positive mutants with significantly increased ARs yield were obtained: M28, M32, and M37. Specifically, the mutations were: isoleucine at position 213 mutated to valine (I213V), leucine at position 271 mutated to valine (L271V), and tyrosine at position 342 mutated to valine (Y342V). After 24 h of fermentation, M28 yielded 35.0 mg / L, an increase of 40.56% compared to the control strain; M32 yielded 37.7 mg / L, an increase of 51.40% compared to the control strain; and M37 yielded 31.1 mg / L, an increase of 24.90% compared to the control strain.

[0046] Example 4: Screening of genetically engineered bacteria with double mutants at the HcPKs3 substrate binding pocket 4.1 Construction of double mutant plasmids at the substrate binding pocket Based on the results of Implementation Case 3, the positive mutants M6, M9, M13, M28, M32, and M37 were combined to obtain mutants with expanded substrate binding pockets and enhanced hydrophobicity, thereby further improving catalytic efficiency and yielding combined mutants with increased yield. The relevant double mutation sites are shown in Table 6. The nine combinations are L211A / I213V, L211A / L271V, L211A / Y342V, F218A / I213V, F218A / L271V, F218A / Y342V, T272A / I213V, T272A / L271V, and T272A / Y342V.

[0047] Specifically: using plasmid pRSFDuet-HcPKs3 containing a single mutation site. (L211A)pRSFDuet-HcPKs3 (F218A) pRSFDuet-HcPKs3 (T272A) Using a template, upstream and downstream primers for the second mutation site were designed. Details of the upstream and downstream primers are shown in Table 7. Whole plasmid PCR amplification was performed using the following PCR program (95℃ 30s; 98℃ 20s, 55℃ 20s, 72℃ 1min, 30 cycles; 72℃ 4min, 16℃ incubation). The amplified plasmid was transformed into *E. coli* DH5α. Single colonies were picked from resistant plates, screened, and sent for sequencing. If sequencing was correct, pRSFDuet-HcPKs3 containing the double mutation site was successfully obtained. (L211A-I213V) pRSFDuet-HcPKs3 (L211A-L271V) pRSFDuet-HcPKs3 (L211A-Y342V) pRSFDuet-HcPKs3 (F218A-I213V) pRSFDuet-HcPKs3 (F218A-L271V) pRSFDuet-HcPKs3 (F218A-Y342V) pRSFDuet-HcPKs3 (T272A--I213V) pRSFDuet-HcPKs3 (T272A--L271V) pRSFDuet-HcPKs3 (T272A--Y342V) The engineered bacteria were used to extract plasmids from the above 9 engineered bacteria using a plasmid extraction kit to obtain recombinant plasmids containing double mutations in the type III polyketide synthase gene sequence.

[0048] Table 6: Double mutants at the substrate binding pocket

[0049] Table 7: Upstream and downstream primers for the second site of the mutant

[0050] 4.2 Construction and fermentation yield determination of double mutant genetically engineered bacteria at the substrate binding pocket The double mutant plasmid pRSFDuet-HcPKs3 will be obtained. (L211A-I213V) pRSFDuet-HcPKs3 (L211A-L271V) pRSFDuet-HcPKs3 (L211A-Y342V) pRSFDuet-HcPKs3 (F218A-I213V) pRSFDuet-HcPKs3 (F218A-L271V) pRSFDuet-HcPKs3 (F218A-Y342V) pRSFDuet-HcPKs3 (T272A--I213V) pRSFDuet-HcPKs3 (T272A--L271V) pRSFDuet-HcPKs3 (T272A--Y342V)The genetically engineered strain containing the double mutant was obtained by electroporation into TCBJ117. Simultaneously, the engineered strain TCBJ117-HcPKs3 was used as the control strain (WT), and the fermentation process and detection methods were the same as in Case 3. Specific results are shown in Table 8.

[0051] Table 8 Yields of Combined Mutants

[0052] In this embodiment, among the nine mutant combinations of M40-M48, seven mutant combinations M40, M43, M44, M45, M46, M47, and M48 showed significantly higher yields than the control group (WT). The mutant with the best substrate binding pocket was M48. Specifically, the mutation was to change threonine at position 272 to alanine (T272A) and tyrosine at position 342 to valine (Y342V), resulting in the highest yield of 67.85 mg / L, which was 172.48% higher than the positive control strain and 2.72 times that of the original strain.

[0053] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A type III polyketide synthase mutant for the production of alkylresorcinol, characterized in that, The type III polyketide synthase mutant is a mutation of amino acid residues near the substrate binding pocket of the type III polyketide synthase, and the amino acid sequence of the type III polyketide synthase is shown in SEQ ID NO.

2.

2. The mutant according to claim 1, characterized in that, The mutation is selected from any one of the following mutations 1-2 or a combination thereof: Mutation 1: Some amino acids located within 5 Å of the substrate binding pocket of type III polyketide synthase are mutated to alanine (Ala), which has less steric hindrance; Mutation 2: Some amino acids located within the 5 Å range of the substrate binding pocket of type III polyketide synthase are mutated to the more hydrophobic valine val.

3. A type III polyketide synthase mutant for the production of alkylresorcinol, characterized in that, The mutation of the type III polyketide synthase mutant satisfies at least one of the following conditions: (1) In mutation 1, the amino acids at positions 55, 59, 62, 63, 160, 211, 213, 217, 218, 237, 258, 271, 272, 275, 276, 314, 316, 317, 319, 320, 342, 347, and 349 of the amino acid sequence of type III polyketide synthase are mutated, and any one of these sites is mutated to alanine; (2) In mutation 2, the amino acids at positions 59, 63, 160, 211, 213, 217, 218, 258, 271, 272, 276, 316, 317, 342, 347, and 349 of the amino acid sequence of type III polyketide synthase are mutated, and any one of these sites is mutated to valine; The amino acid sequence of the type III polyketide synthase is shown in SEQ ID NO.

2.

4. The mutant according to claim 3, characterized in that, The mutation of the type III polyketide synthase mutant is any combination between mutation 1 and mutation 2.

5. A type III polyketide synthase mutant, characterized in that, The mutation of the type III polyketide synthase mutant is any one of the following ①-②: ①: One or more of L211A, F218A, T272A, I213V, L271V, and Y342V; ②: One or more of L211A / I213V, F218A / I213V, F218A / L271V, F218A / Y342V, T272A / I213V, T272A / L271V, and T272A / Y342V.

6. A nucleic acid molecule, characterized in that, The nucleic acid molecule includes a nucleotide sequence encoding a type III polyketide synthase mutant as described in any one of claims 1-5.

7. An expression carrier, characterized in that, The expression vector contains the nucleic acid molecule as described in claim 6; preferably, the expression vector is a plasmid vector.

8. A genetically engineered bacterium, characterized in that, The genetically engineered bacteria contain the expression vector described in claim 7.

9. The genetically engineered bacterium according to claim 8, characterized in that, The chassis bacteria of the genetically engineered bacteria are one of Escherichia coli, Corynebacterium glutamicum, and Bacillus subtilis.

10. A method for producing alkylresorcinol, characterized in that, The method uses the type III polyketide synthase mutant of any one of claims 1-5 as a catalyst to catalyze the synthesis of alkyl resorcinol.

Citation Information

Patent Citations

  • T7 expression system-based Nissel 1917 engineering bacterium as well as preparation method and application of T7 expression system-based Nissel 1917 engineering bacterium

    CN118931930A